384 related articles for article (PubMed ID: 20972656)
1. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
Więcek A; Ahmed I; Scigalla P; Koytchev R
Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
Haag-Weber M; Vetter A; Thyroff-Friesinger U;
Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
[TBL] [Abstract][Full Text] [Related]
6. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
Spinowitz BS; Pratt RD;
Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
Milutinović S; Plavljanić E; Trkulja V
Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
[TBL] [Abstract][Full Text] [Related]
9. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Jacobs C; Frei D; Perkins AC
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
11. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
13. Relative mortality and epoetin alpha dose among hemodialysis patients.
Coyne DW
Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
[No Abstract] [Full Text] [Related]
14. Relative mortality and epoetin alpha dose in hemodialysis patients.
Cotter DJ; Thamer M; Zhang Y
Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
[No Abstract] [Full Text] [Related]
15. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients.
Loughnan A; Ali GR; Abeygunasekara SC
Ren Fail; 2011; 33(3):373-5. PubMed ID: 21401367
[TBL] [Abstract][Full Text] [Related]
17. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
Macdougall IC; Temple RM; Kwan JT
Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Rossert J; Gassmann-Mayer C; Frei D; McClellan W
Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
[TBL] [Abstract][Full Text] [Related]
19. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
Pussell BA; Walker R
Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
[TBL] [Abstract][Full Text] [Related]
20. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
